MedVellum
MedVellum
Back to Library
Endocrinology
Genetics
Gastroenterology
EMERGENCY

Acute Intermittent Porphyria (AIP)

High EvidenceUpdated: 2025-12-22

On This Page

Red Flags

  • Neurovisceral Crisis
  • Respiratory paralysis
  • Seizures
Overview

Acute Intermittent Porphyria (AIP)

1. Clinical Overview

Summary

Acute Intermittent Porphyria (AIP) is an autosomal dominant disorder of heme biosynthesis caused by deficiency of porphobilinogen deaminase. Accumulation of porphyrin precursors (ALA, PBG) causes neurovisceral attacks triggered by drugs, fasting, or hormonal changes.

Key Facts

AspectDetail
InheritanceAutosomal dominant
Enzyme DefectPorphobilinogen (PBG) deaminase (50% activity)
Key FindingElevated urinary PBG during attack
Classic FeaturePort-wine coloured urine
TreatmentHaem arginate + glucose loading

Clinical Pearls - The 5 Ps

  1. Painful abdomen - severe, colicky, mimics surgical abdomen
  2. Port-wine urine - darkens on standing (oxidation of PBG)
  3. Polyneuropathy - motor > sensory, may cause paralysis
  4. Psychological - confusion, anxiety, psychosis
  5. Precipitated by drugs - P450 inducers, fasting, hormones

2. Epidemiology

Demographics

FactorDetail
Prevalence1-2 per 100,000
GenderFemales > Males (hormonal triggers)
Peak age18-40 years
Penetrance~10-20% carriers develop symptoms

Triggers

CategoryExamples
DrugsBarbiturates, sulfonamides, rifampicin, phenytoin, alcohol
HormonesProgesterone, menstrual cycle, OCP
MetabolicFasting, low carbohydrate diets
StressInfection, surgery
Smoking

3. Pathophysiology

Heme Biosynthesis Defect

Glycine + Succinyl-CoA
         ↓ (ALAS - rate-limiting)
δ-Aminolevulinic Acid (ALA)
         ↓
Porphobilinogen (PBG)
         ↓ (PBG Deaminase - DEFICIENT in AIP)
    ████ BLOCK ████
         ↓
ALA + PBG ACCUMULATE
         ↓
NEUROTOXICITY (autonomic, motor, CNS)
         ↓
ACUTE ATTACK

Why Triggers Cause Attacks

  • P450 inducers → ↑ demand for heme → ↑ ALAS activity → more ALA/PBG production
  • Fasting → ↓ glucose → ↑ ALAS → same effect
  • Progesterone → induces ALAS

4. Clinical Presentation

Acute Attack Features

SystemManifestations
GISevere abdominal pain (colicky), vomiting, constipation
NeurologicalMotor neuropathy, weakness, paralysis
PsychiatricConfusion, anxiety, depression, psychosis
AutonomicTachycardia, hypertension, sweating
UrinaryDark/red urine (port-wine)
ElectrolytesHyponatraemia (SIADH)

Danger Signs

SignConcern
Respiratory weaknessMay need ventilation
Bulbar weaknessAspiration risk
SeizuresUsually due to hyponatraemia
QuadriparesisSevere motor neuropathy

5. Clinical Examination

Findings During Attack

FindingNotes
TachycardiaAutonomic dysfunction
HypertensionCommon
Abdominal tendernessOften NO peritonism (soft)
Reduced reflexesMotor neuropathy
Proximal weaknessMotor predominant
ConfusionCNS involvement

Key Point

  • Normal abdomen on exam despite severe pain - no guarding = think AIP

6. Investigations

Diagnostic Tests

TestFindingNotes
Urine PBG (spot)ELEVATED (x20-100 normal)Gold standard during attack
Urine ALAElevated
Urine colourPort-wine, darkens on standingClassic

Supporting Tests

TestPurpose
FBC, U&EHyponatraemia common
LFTsMay be deranged
Genetic testingHMBS gene mutation
Erythrocyte PBG deaminaseReduced (but overlaps with carriers)

Exclude Surgical Abdomen

  • AXR, CT usually normal
  • Lactate normal
  • No peritonism

7. Management

Acute Attack Management

StepIntervention
1. Stop triggersIdentify and stop precipitating drugs
2. IV glucose10% dextrose infusion (300-500g/day)
3. Haem arginate3mg/kg/day IV for 4 days
4. AnalgesiaOpioids safe (pethidine traditionally used)
5. AntiemeticsOndansetron, prochlorperazine safe
6. MonitorHyponatraemia, respiratory function

Safe Drugs

CategoryExamples
AnalgesiaMorphine, fentanyl, paracetamol
AntiemeticsOndansetron
SedationBenzodiazepines (short-acting)
AntibioticsPenicillins, cephalosporins

Unsafe Drugs (Avoid)

CategoryExamples
AnticonvulsantsPhenytoin, barbiturates, valproate
AntibioticsSulfonamides, rifampicin
OthersAlcohol, hormones, ergots

Prevention

MeasureDetails
Avoid triggersDrug list, avoid fasting
Regular carbohydrateAvoid low-carb diets
HormonalGnRH analogues if menstrual trigger
Prophylactic haem arginateFor frequent attacks
GivosiranNew RNAi therapy (reduces ALAS1)

8. Complications
ComplicationNotes
Respiratory failureMotor neuropathy
Bulbar paralysisAspiration
Chronic painBetween attacks
HyponatraemiaSIADH
Hepatocellular carcinomaLong-term risk (screen annually >0y)
Chronic kidney diseaseLong-term

9. Prognosis & Outcomes
FactorOutcome
With treatmentMost attacks resolve in days
Motor neuropathyMay take months to recover
Long-termGenerally good if triggers avoided
HCC riskAnnual liver USS recommended >0 years

10. Evidence & Guidelines
OrganisationKey Points
British Porphyria AssociationDrug lists, patient support
EPNETEuropean porphyria network
NICEGivosiran recommendation

11. Patient / Layperson Explanation

What is AIP? It's a rare inherited condition affecting how your body makes a substance called heme (part of haemoglobin). When triggered, your body makes too much of certain chemicals that affect your nerves and cause symptoms.

What are the symptoms of an attack?

  • Severe tummy pain
  • Nausea and vomiting
  • Dark red ("port wine") urine
  • Weakness in arms/legs
  • Confusion or anxiety
  • Fast heartbeat

What causes attacks?

  • Certain medications (we'll give you a list of safe ones)
  • Not eating (fasting or low-carb diets)
  • Alcohol
  • Hormonal changes (periods, pregnancy)
  • Infections

How is it treated?

  • During attack: IV drip with sugar solution and a medication called haem arginate
  • Prevention: Avoid triggers, keep a list of safe medications
  • New treatments: A drug called givosiran can prevent attacks

What can I do?

  • Carry a card explaining your condition
  • Keep a list of safe medications
  • Don't fast or skip meals
  • Avoid alcohol
  • Tell doctors before any surgery or new medication

12. References
  1. British Porphyria Association. www.porphyria.org.uk
  2. Anderson KE, et al. Recommendations for the diagnosis and treatment of AIP. Ann Intern Med. 2005.
  3. Balwani M, et al. Givosiran in AIP. NEJM. 2020.

Last updated: 2025-12-22

At a Glance

EvidenceHigh
Last Updated2025-12-22
Emergency Protocol

Red Flags

  • Neurovisceral Crisis
  • Respiratory paralysis
  • Seizures

Clinical Pearls

  • sensory, may cause paralysis
  • Males (hormonal triggers) |

Guidelines

  • NICE Guidelines
  • BTS Guidelines
  • RCUK Guidelines